Clinical Trials for Small Cell Lung Cancer

A Front-Line Window-of-Opportunity Phase 2 Study of Tarlatamab (Bispecific T Cell Engager: DLL3-CD3) in Patients With Extensive-Stage Small-Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with newly diagnosed extensive-stage (metastatic/recurrent) small-cell lung cancer (ECOG 0–2) with measurable disease, including treated/stable asymptomatic brain metastases and select asymptomatic untreated brain metastases without edema. Patients receive first-line tarlatamab IV monotherapy (DLL3×CD3 bispecific T-cell engager redirecting T cells to DLL3-expressing SCLC) on a window-of-opportunity basis, with early progressors at 4 weeks transitioning to standard platinum chemotherapy plus an immune checkpoint inhibitor, and close monitoring for CRS/ICANS.

ClinicalTrials.gov ID: NCT07423585

Feasibility Trial of Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with HPV-negative, PD-L1 CPS >1 recurrent/metastatic head and neck squamous cell carcinoma, no prior checkpoint inhibitor therapy, and an ultrasound- and biopsy-accessible measurable lesion. Patients receive pembrolizumab, an anti–PD-1 antibody, with Definity perflutren microbubbles and tumor-directed ultrasound-induced cavitation intended to enhance intratumoral drug delivery and immune response.

ClinicalTrials.gov ID: NCT07501650

A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients With Advanced Non-Small Cell Lung Cancer With a KRASG12C Mutation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced/metastatic KRAS G12C–mutant NSCLC after prior KRAS G12C inhibitor, immune checkpoint inhibitor, and platinum chemotherapy receive sotorasib, an oral covalent KRAS G12C inhibitor, plus trastuzumab deruxtecan, a HER2-directed topoisomerase I payload antibody-drug conjugate. The study includes dose escalation followed by expansion to assess safety and response, with treated or selected asymptomatic active brain metastases allowed and ILD/pneumonitis excluded.

ClinicalTrials.gov ID: NCT07012031

Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with stage IIIB/IV NSCLC without sensitizing EGFR or ALK/ROS1 alterations receiving first-line standard PD-1/PD-L1–based therapy ± chemotherapy undergo serial ctDNA/biomarker monitoring to guide immunotherapy duration or discontinuation. At progression, biomarker-selected cohorts receive tremelimumab (anti–CTLA-4) plus durvalumab (anti–PD-L1) for STK11/KEAP1-mutant disease or adagrasib (KRAS G12C inhibitor) plus bevacizumab (anti-VEGF) for KRAS G12C-mutant disease.

ClinicalTrials.gov ID: NCT07288034

Pilot Study of 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy (SBRT) for Oligo-Progressive Non-Small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with stage IV NSCLC receiving single-agent pembrolizumab who have both oligoprogressive and nonprogressing lesions undergo SBRT to up to six oligoprogressive sites while continuing pembrolizumab; selected nonprogressing lesions may receive low-dose radiation. They also receive investigational 64Cu-DOTA-pembrolizumab, a radiolabeled PD-1–targeting antibody used for PET imaging before and after radiation rather than as an additional therapeutic dose.

ClinicalTrials.gov ID: NCT07619599

Combination Of Izalontamab Brengitecan And Adagrasib In Advanced KRAS G12Ci-Refractory Non-Small Cell Lung Cancer - The IZA-A Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, incurable KRAS G12C-mutant NSCLC that has progressed on a prior KRAS G12C inhibitor receive adagrasib, a KRAS G12C inhibitor, plus investigational izalontamab brengitecan, an EGFR/HER3-directed antibody-drug conjugate carrying a topoisomerase I inhibitor payload. Eligible patients have received 1–3 prior lines of therapy and have ECOG performance status 0–1.

ClinicalTrials.gov ID: NCT07382726

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic ALK-positive NSCLC who have received and tolerated lorlatinib are treated with lorlatinib plus escalating doses of NXP900, an oral SRC-family kinase inhibitor targeting YES1 and SRC. The study particularly addresses disease progression or acquired resistance during lorlatinib treatment.

ClinicalTrials.gov ID: NCT07784959

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants With Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-315)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable extensive-stage small-cell lung cancer that has progressed or recurred after exactly one platinum-based regimen and ECOG performance status 0–1 are randomized to subcutaneous or intravenous tarlatamab. Tarlatamab is a DLL3-directed CD3 bispecific T-cell engager; the study primarily compares drug exposure between administration routes.

ClinicalTrials.gov ID: NCT07778316

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced NSCLC unsuitable for definitive therapy or metastatic NSCLC receive oral ABSK112, an investigational brain-penetrant kinase inhibitor designed to target EGFR exon 20 insertions while relatively sparing wild-type EGFR. Dose expansion requires a documented EGFR exon 20 insertion; patients with EGFR C797S mutations are excluded.

ClinicalTrials.gov ID: NCT06225804

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves patients with oligoprogressive non-small cell lung cancer who previously received first-line systemic therapies, evaluating the safety of adding the antimicrobial agent vancomycin to precision hypofractionated radiation therapy. Vancomycin, known for inhibiting bacterial cell wall synthesis, is used here to potentially reduce infections and modulate the immune response.

ClinicalTrials.gov ID: NCT03546829